within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05A_ParathyroidHormonesAndAnalogues.H05AA02_Teriparatide;

model Teriparatide
  extends Pharmacolibrary.Drugs.ATC.H.H05AA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H05AA02</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture. It stimulates new bone formation by acting on osteoblasts. Teriparatide is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following a single subcutaneous dose of 20 mcg in healthy adult volunteers (both sexes).</p><h4>References</h4><ol><li><p>Imai, H, et al., &amp; Moritoyo, T (2014). Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. <i>International journal of clinical pharmacology and therapeutics</i> 52(2) 166–174. DOI:<a href=\"https://doi.org/10.5414/CP202001\">10.5414/CP202001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24361089/\">https://pubmed.ncbi.nlm.nih.gov/24361089</a></p></li><li><p>Kumagai, Y, et al., &amp; Sugimoto, T (2020). Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study. <i>Clinical pharmacology in drug development</i> 9(1) 87–96. DOI:<a href=\"https://doi.org/10.1002/cpdd.687\">10.1002/cpdd.687</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30921502/\">https://pubmed.ncbi.nlm.nih.gov/30921502</a></p></li><li><p>Satterwhite, J, et al., &amp; Dobnig, H (2010). Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. <i>Calcified tissue international</i> 87(6) 485–492. DOI:<a href=\"https://doi.org/10.1007/s00223-010-9424-6\">10.1007/s00223-010-9424-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20953593/\">https://pubmed.ncbi.nlm.nih.gov/20953593</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Teriparatide;
